抗体药物偶联物市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00003494
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 178
Buy Now

【研究报告】抗体药物偶联物市场规模预计将从2022年的77.9343亿美元增至2030年的296.0098亿美元;预计 2022 年至 2030 年该市场的复合年增长率将达到 18.2%。
市场洞察和分析师观点:
抗体药物偶联物或 ADC 是有助于将化疗药物递送至癌细胞的靶向药物。化疗物质与单克隆抗体连接,以促进其与癌细胞表面表达的特定靶标结合。 ADC由于其杀伤癌细胞的准确性和效率,已成为抗癌药物研发的主要热点之一。开发抗体药物偶联物的战略合作伙伴关系不断发展、癌症病例发病率上升以及 FDA 对 ADC 的批准不断增加,推动了市场的增长。另一方面,ADC 开发和商业化的高成本阻碍了抗体药物偶联物市场的增长。
增长动力:
癌症发病率上升推动抗体药物偶联物市场增长
癌症发病率上升是主要增加了对创新癌症治疗的需求。根据全球癌症观察站 (GLOBOCAN) 2020 年发布的估计,全球有 1930 万癌症病例。美国、中国和印度是癌症病例数最多的国家。 GLOBOCAN 还估计,到 2040 年,印度的癌症病例将达到约 208 万例,较 2020 年增加 57.5%。根据世界卫生组织 (WHO) 2022 年 2 月发布的数据,全球约有 1000 万人死亡来自癌症。最常见的癌症类型是肺癌、乳腺癌、结肠癌和直肠癌、前列腺癌和乳腺癌。癌症发病率的上升引起了全世界的关注。下面提供了 2020 年全球报告的常见癌症病例列表。
2020 年全球新癌症病例
Sr.数量
癌症类型
病例(百万)
1
胃癌
1.09
2
皮肤(非黑色素瘤)
1.2
3
前列腺
1.41
4
结肠和直肠
1.93
5

2.21
6
乳房
2.26
来源:世界卫生组织组织,2020 年 2 月
癌症现在是一种生活方式疾病,常见于饮食习惯不健康和缺乏运动的人群。此外,饮酒和吸烟也会增加患癌症的风险。低收入和中等收入国家的慢性传染病可进一步加剧癌症危险因素。根据世界卫生组织2022年2月公布的数据,2018年诊断的近18%是人乳头瘤病毒(HPV)、幽门螺杆菌、乙型肝炎病毒、丙型肝炎病毒和EB病毒等慢性传染病。 ADC 有希望的结果预计将加速其作为有效癌症治疗的需求。
战略见解
报告细分和范围:
“抗体药物偶联物市场”根据技术、应用和领域进行细分分销渠道。根据技术,抗体药物偶联物市场分为可切割和不可切割连接体。 2022 年,可裂解连接子细分市场占据了更大的市场份额,而不可裂解连接子细分市场预计在 2022-2030 年期间复合年增长率更快。根据应用,抗体药物偶联物市场分为血癌、乳腺癌、卵巢癌、尿路上皮癌等。 2022 年,乳腺癌细分市场占据最大市场份额,预计 2022 年至 2030 年复合年增长率最快。抗体药物偶联物市场按分销渠道分为零售药房、医院药房等。 2022年,医院药房细分市场占据最大的市场份额,预计该细分市场在2022-2030年期间将创下最快的复合年增长率。
细分市场分析:
从技术角度来看,抗体药物偶联物市场分为可裂解和可裂解的市场。和不可切割的接头。 2022 年,可裂解连接子细分市场占据了更大的市场份额,而不可裂解连接子细分市场预计在 2022-2030 年期间复合年增长率更快。不可裂解连接体进一步分为硫醚或马来酰亚胺己酰基(MC)基团连接体。与可裂解接头不同,不可裂解 ADC 更依赖于靶细胞的生物学特性。使用不可切割连接器技术开发的 ADC 显示有效负载效力降低。该技术提高了血浆稳定性并提高了癌症治疗的治疗指数。许多研究表明,用于 ADC 体内开发的不可裂解接头技术比可裂解接头技术表现更好。此外,不可裂解接头技术提供了比可裂解接头更大的潜在治疗窗口,从而使 ADC 有效负载衍生物能够更有效地杀死靶细胞。
按技术划分的抗体药物偶联物市场 – 2022 年和 2030 年
基于应用,抗体药物偶联物市场分为血癌、乳腺癌、卵巢癌、尿路上皮癌等。 2022年,乳腺癌细分市场占有最大的市场份额,进一步估计2022-2030年的复合年增长率最快为18.6%。 ADC 的使用显着改变了乳腺癌治疗的计划方式。 ADC 的开发有望提高乳腺癌治疗的效力、精确度和安全性。目前,市场上治疗三阴性乳腺癌(TNBC)的商业化产品有Kadcyla/T-DM1(ado-trastuzumab emtansine)、Enhertu/T-DXd(trastuzumab deruxtecan)和Trodelvy/SG(sacituzumab govetican) )和转移性乳腺癌病例。根据乳腺癌研究基金会 2023 年 1 月发布的数据,有 17 种 ADC 正在进行临床试验。其中 9 个是针对 HER2 的 ADC,正在以不同的有效负载组合进行研究。其余 8 种 ADC 正在与新型抗体靶点结合进行研究。
抗体药物偶联物市场按分销渠道分为零售药房、医院药房等。 2022年,医院药房细分市场占据最大市场份额,预计2022-2030年复合年增长率将达到18.5%,为最快。医院药房是融入医院、诊所、戒毒所等医疗保健中心的专业药房。医院药房广泛分发处方药。 ADC 被规定为治疗癌症的先进疗法,因此,它们的分配需要更多的关注和护理。因此,ADC 通过医院药房广泛分发。此外,医院药房有能力支持大量库存的存储。
根据医疗保健计划购买的药品的报销是医院药房提供的主要福利。他们还拥有专门的库存和储存设施,甚至用于研究药物(正在研究但尚未获得批准),这是其他社区环境所没有的。另一方面,医院药房不是零售场所,不为非住院患者提供药物。他们可以直接从制造商或供应商那里购买药品,从而消除了漫长的分销网络。
区域分析 - 抗体药物偶联物市场:
根据地理位置,抗体药物偶联物市场分为五个关键区域:北美、欧洲、亚太地区、南美洲和中美洲、中东和非洲。 2022年,北美占据抗体药物偶联物市场的最大份额。预计 2022 年至 2030 年,亚太地区将成为全球抗体药物偶联物市场最高的复合年增长率。
北美在抗体药物偶联物市场中占有最大份额。该地区的市场分为美国、加拿大和墨西哥。该地区的市场增长归因于 ADC 研发的不断增加;产品批准量不断增加;提高对 ADC 的认识;市场参与者之间的合并、合作和伙伴关系数量激增。此外,癌症发病率的显着上升也推动了对 ADC 的需求。美国是北美乃至全球抗体药物偶联物市场的最大贡献者。美国批准的 ADC 数量最多。到 2021 年 1 月,美国食品和药物管理局 (FDA) 已批准 Mylotarg、Lumoxiti、Adcetris、Kadcyla、Enhertu、Trodelvy、Besponsa、Polivy、Padcev 和 Blenrep 用于多种癌症适应症。此外,美国还有多个 ADC 正在研发中。 ADC 的开发采用了先进的偶联技术、更有效的有效负载、针对新型抗原和新型接头等策略。根据 FDA 2021 年 5 月发布的数据,针对 77 种新型 ADC 的 113 项临床试验正在进行中,针对 40 多个不同靶点。
亚太地区抗体药物偶联物 (ADC) 市场细分为中国、日本、印度、韩国、澳大利亚和亚太地区其他地区。该地区 ADC 市场的增长广泛受到公司之间的合作、癌症发病率上升以及临床试验数量增加的推动。中国是各种 ADC 创新者的所在地,这些创新者为市场增长做出了指数级的贡献。荣昌生物等玩家;浙江医药股份有限公司;江苏恒瑞药业有限公司是国内ADC市场的领先者。这些公司参与开发治疗乳腺癌、胃癌和尿路上皮癌的 ADC。公司有多种产品正在研发中,准备在临床试验完成后投放市场。 2023年6月,荣昌生物与信达生物签署协议,进入临床试验并提供达伯舒(信迪利单抗注射液)与新型间皮素靶向(MSLN靶向)抗体药物偶联物RC88的联合疗法。 ADC) 或达伯舒 (TYVYT) 与 RC108,这是一种新型 c-Met 靶向 ADC。这些据称是治疗实体瘤的新疗法。根据协议,荣昌生物将对达伯舒进行1/2a期临床研究,以评估其抗肿瘤活性和安全性。该公司还有 Distamab vedotin (RC48) + PD1 组合正在研发中。该组合分两个阶段针对不同适应症进行评估;第一个组合处于 III 期阶段,用于评估其治疗尿路上皮癌的疗效,而第二个组合处于 II 期阶段,用于检查其治疗肌肉浸润性膀胱癌和胃癌的能力。
行业发展和未来机遇 –抗体药物偶联物市场:
抗体药物偶联物市场领先企业采取的各种举措如下:
2023年6月,信达生物制药与荣昌生物达成临床试验合作达伯舒(信迪利单抗注射液)与RC88(一种新型间皮素(MSLN)靶向ADC)或RC108(一种新型c-Met靶向ADC)联合疗法的供应协议,作为中国晚期实体瘤的潜在治疗选择。根据协议,信达生物将在临床试验合作期间提供达伯舒(信迪利单抗注射液)的临床药品供应。荣昌生物将开展1/2a期临床试验,研究达伯舒(信迪利单抗注射液)联合RC88或RC108联合治疗中国晚期实体瘤患者的安全性和抗肿瘤活性。 2022年7月,阿斯利康签署新的全球开发和商业化协议与第一三共株式会社 (Daiichi Sankyo) 就 DS-1062 达成协议,这是第一三共的专有 ADC,针对滋养层细胞表面抗原 2 (TROP2),这是一种治疗多种肿瘤类型的潜在新药。 DS-1062 目前正处于开发阶段,其针对多种通常表达 TROP2(一种细胞表面糖蛋白)的肿瘤的活性。 TROP2 在几乎所有非小细胞肺癌 1 和乳腺癌 2,3 肿瘤类型中过度表达,长期以来一直是阿斯利康的战略重点。此次合作表明阿斯利康通过与第一三共的成功现有合作来投资 ADC 的战略。 2022 年 1 月,吉利德科学公司与默沙东(加拿大和美国以外的 MSD)签订了两项临床试验合作和供应协议,以评估吉利德的 Trodelvy(sacituzumab govitecan-hziy)靶向 TROP-2 的 ADC 和默克的抗 PD-1 疗法 KEYTRUDA(pembrolizumab)的组合。作为此次合作的一部分,默克预计将赞助 Trodelvy 联合 KEYTRUDA 作为转移性 NSCLC 患者一线治疗的全球 3 期临床试验。竞争格局和主要公司 - 抗体药物偶联物市场:
ADC Therapeutics南澳;辉瑞公司; F.霍夫曼-拉罗氏有限公司;免疫原公司;葛兰素史克公司;吉利德科学公司;阿斯利康公司;安斯泰来制药公司;荣昌生物 (RemeGen Co Ltd) 和武田制药 (Takeda Pharmaceutical Co Ltd) 是抗体药物偶联物市场的知名公司。这些公司专注于新技术、现有产品的进步和地域扩张,以满足全球不断增长的消费者需求。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Who are the major players in the Antibody Drug Conjugates Market?

The antibody drug conjugates market majorly consists of the players such as ADC Therapeutics, Gilead Sciences, Inc, AstraZeneca, RemeGen, Roche, GSK, and Takeda, ImmunoGen, Astellas, Pfizer.

What are the driving factors for the Antibody Drug Conjugates Market?

The growth of the market is attributed to the growing strategic partnerships to develop of antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs. Whereas high cost of ADCs development and commercialization is hindering the market growth.

Which region is dominating the Antibody Drug Conjugates Market

The antibody drug conjugates (ADCs) market is analyzed based on North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. North America is expected to hold significant market share in 2022. North America is analyzed based on the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs, rising product approvals, growing awareness about ADCs, and rising number of mergers, collaborations, and partnerships among the operating players. In addition, significantly growing incidences of cancer are among the other leading factors escalating the demand for ADCs.

What is Antibody Drug Conjugates?

Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker.

Which segment is dominating the Antibody Drug Conjugates Market?

Based on application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share, and is estimated to register the fastest CAGR during 2022–2030.

The List of Companies - Antibody Drug Conjugates Market

  1. ADC Therapeutics SA
  2. Pfizer Inc.
  3. F. Hoffmann-La Roche Ltd
  4. ImmunoGen, Inc.
  5. GSK Plc
  6. Gilead Sciences Inc.
  7. AstraZeneca Plc
  8. Astellas Pharma Inc.
  9. RemeGen Co Ltd
  10. Takeda Pharmaceutical Co Ltd

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports